A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
At a glance
- Drugs AGN-242071 (Primary) ; Donepezil; Memantine
- Indications Alzheimer's disease
- Focus Adverse reactions; Diagnostic use; Pharmacokinetics; Therapeutic Use
- Sponsors Allergan
- 13 Jun 2018 Planned initiation date changed from 20 May 2018 to 30 Jul 2018.
- 13 Apr 2018 Planned initiation date changed from 13 Apr 2018 to 20 May 2018.
- 12 Mar 2018 Planned initiation date changed from 20 Feb 2018 to 13 Apr 2018.